The Eye As a Biomarker for Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and eventual death. It is the leading cause of dementia and the number of cases are projected to rise in the next few decades. Pathological hallmarks of AD include the presence of hyperphosphorylated tau and amyloid protein deposition. Currently, these pathological biomarkers are detected either through cerebrospinal fluid analysis, brain imaging or post-mortem. Though effective, these methods are not widely available due to issues such as the difficulty in acquiring samples, lack of infrastructure or high cost. Given that the eye possesses clear optics and shares many neural and vascular similarities to the brain, it offers a direct window to cerebral pathology. These unique characteristics lend itself to being a relatively inexpensive biomarker for AD which carries the potential for wide implementation. The development of ocular biomarkers can have far implications in the discovery of treatments which can improve the quality of lives of patients. In this review, we consider the current evidence for ocular biomarkers in AD and explore potential future avenues of research in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
A review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · cited 1×
“Given that PET imaging detected amyloid deposition in the brain well before the onset of clinical symptoms in AD (Pike et al., 2007; Rowe et al., 2007), retinal imaging of in vivo Aβ accumulation is an exciting prospect.”
BackgroundBurns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · cited 1×
“Given that PET imaging detected amyloid deposition in the brain well before the onset of clinical symptoms in AD (Pike et al., 2007; Rowe et al., 2007), retinal imaging of in vivo Aβ accumulation is an exciting prospect.”
BackgroundAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
Koronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., & Farkas, D. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.020 · Cited by 672
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
Quantitative assessment of cortical synaptic density in Alzheimer's disease
Scheff, S. W., DeKosky, S. T., & Price, D. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90059-9 · Cited by 446 · cited 1×
“This may account for why synaptic density is the best correlate of cognitive decline in AD (DeKosky and Scheff, 1990; Scheff et al., 1990, 1993, 2007; Terry et al., 1991; Masliah et al., 1994; Ingelsson et al., 2004), which may also explain why the macular ganglion cell complex is more sensitive to…”
BackgroundSynaptic and neuritic alterations during the progression of Alzheimer's disease
Masliah, E., Mallory, M., Hansen, L., Richard, D., Alford, M., & Terry, R. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90121-x · Cited by 370
Anderson, D. H., Talaga, K. C., Rivest, A. J., Barron, E., Hageman, G. S., & Johnson, L. V. (2004) · Experimental Eye Research · doi:10.1016/j.exer.2003.10.011 · Cited by 319 · cited 2×
“It has been known formore than a decade that Aβ is found in drusen deposits in eyes with age-related macular degeneration but not in normal retinas (Johnson et al., 2002; Dentchev et al., 2003; Anderson et al., 2004).”
BackgroundAmyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318
Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease
Frost, S., Kanagasingam, Y., Sohrabi, H., Vignarajan, J., Bourgeat, P., Salvado, O., Villemagne, V, Rowe, C. C., Lance Macaulay, S., Szoeke, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.150 · Cited by 297
MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons
Mandelkow, E.-M., Thies, E., Trinczek, B., Biernat, J., & Mandelkow, E. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200401085 · Cited by 236
Liu, B., Rasool, S., Yang, Z., Glabe, C. G., Schreiber, S. S., Ge, J., & Tan, Z. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090159 · Cited by 182 · cited 2×
“Whilst better segmentation algorithms are already available to overcome the current limitations, the biggest challenge is that choroidal thinning undergoes significant diurnal fluctuations (Kinoshita et al., 2016) and its thinning is seen in many other conditions, including aging (Barteselli et…”
BackgroundReduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging
Danesh-Meyer, H. V., Birch, H., Ku, J. Y.-F., Carroll, S., & Gamble, G. (2006) · Neurology · doi:10.1212/01.wnl.0000244490.07925.8b · Cited by 164
Gasparini, L., Anthony Crowther, R., Martin, K. R., Berg, N., Coleman, M., Goedert, M., & Spillantini, M. G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.002 · Cited by 133 · cited 1×
“In addition to synaptic loss, early change to neurons includes the disruption of microtubules (Matsuyama and Jarvik, 1989; Mandelkow et al., 2004; Gasparini et al., 2011).”
BackgroundHoh Kam, J., Lenassi, E., & Jeffery, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013127 · Cited by 131 · cited 4×
“In humans, Hoh et al. (2010) also reported that Aβ accumulated in photoreceptor outer segments in post-mortem retina of AD patients.”
BackgroundInfluentialKrasodomska, K., Lubiński, W., Potemkowski, A., & Honczarenko, K. (2010) · Documenta Ophthalmologica · doi:10.1007/s10633-010-9238-x · Cited by 127
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · cited 1×
“Carriers of the apolipoprotein E (APOE) ǫ4 allele (13.7% of the world’s population) face an increased risk of developing the disease (Farrer et al., 1997), depending on whether they have one or two copies of the ǫ4 allele.”
BackgroundInfluentialHypothesis: microtubules, a key to Alzheimer disease
Matsuyama, S. S., & Jarvik, L. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.8152 · Cited by 95
Current thinking on the mechanistic basis of Alzheimer's and implications for drug development
Ising, C., Stanley, M., & Holtzman, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.200 · Cited by 59 · cited 1×
“There is a growing need for a biomarker in Alzheimer’s disease as recent clinical findings suggest that successful treatment needs to start in the prodromal stages of the disease (Ising et al., 2015).”
Background
Cited by
The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma.
Ramirez, A. I., de Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., López-Cuenca, I., Rojas, P., Triviño, A., & Ramírez, J. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00214 · Cited by 466
Hadoux, X., Hui, F., Lim, J. K. H., Masters, C. L., Pébay, A., Chevalier, S., Ha, J., Loi, S., Fowler, C. J., Rowe, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12242-1 · Cited by 304
Self-citationEvaluation of optical coherence tomography angiographic findings in Alzheimer’s type dementia
Bulut, M., Kurtuluş, F., Gözkaya, O., Erol, M. K., Cengiz, A., Akıdan, M., & Yaman, A. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-310476 · Cited by 276
Alber, J., Goldfarb, D., Thompson, L. I., Arthur, E., Hernandez, K., Cheng, D., DeBuc, D. C., Cordeiro, F., Provetti‐Cunha, L., den Haan, J., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12006 · Cited by 154
Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Metadata
- Authors
- Lim, J. K. H., Li, Q.-X., He, Z., Vingrys, A. J., Wong, V. H. Y., Currier, N., Mullen, J., Bui, B. V., & Nguyen, C. T. O.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2016-11-17
- Volume
- 10
- Pages
- 536-536
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2551410102
- Cited by
- 209
- References
- 24
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.